Thank you to Andrew Dunn for this reporting and the opportunity to discuss how Iambic has realized the remarkable power of AI and machine learning - integrated with automated experimentation - to rapidly discover, design and deliver to the clinic highly differentiated drug development candidates. #AI #ML #drugdiscovery #endpointsnews
In the first months of building their startup, Thomas Miller and Fred Manby asked Derek Lowe to join their scientific advisory board. Lowe, as most in the industry know, writes an influential blog on the industry's happenings, particularly in dispensing a sobering, grounded view on the AI hype surrounding biology. By bringing in Lowe — the only AI biotech that Lowe has formally advised — Iambic Therapeutics built some pragmatism into its DNA. “It hasn’t always been the most cheerful advice for any computational company to hear,” Lowe said in an interview. “I’m not going to be someone who just comes in and tells them, ‘Yeah, looks great. You guys are wonderful.’ You can get a lot of people doing that for you.” That level-headedness carries through today, as the Iambic team is focused on making real drugs with its AI software. In my latest for Endpoints News, I visited Iambic's labs to see how its software works and the next steps for Miller and Manby's fast-growing startup:
